CAR T-cell Therapy Articles

Best Practices With CAR T-Cell Therapy Being Refined in Lymphomas
Alison R. Sehgal, MD, discusses the latest developments with CAR T-cell therapy in lymphomas.
Expert Highlights CAR-T and Other Treatment Advances Across Hematologic Malignancies
Mazyar Shadman, MD, MPH, discusses earlier use of CAR T-cell therapy in lymphoma, the impact of approved products on future development, and recent data with chemotherapy-free and time-limited therapy in chronic lymphocytic leukemia.
Concurrent Ibrutinib With CAR T-Cell Therapy Improves ORR, Reduces Severe CRS in High-Risk CLL
Patients with high-risk relapsed/refractory chronic lymphocytic leukemia who failed or were intolerant of ibrutinib derived more benefit from CD19‐targeted CAR T-cell therapy when the BTK inhibitor was concurrently administered than when it was not.
Lisocabtagene Maraleucel Continues to Show Promise in Relapsed/Refractory CLL
The CAR T-cell therapy lisocabtagene maraleucel demonstrated high rates of response, including minimum residual disease in blood and marrow in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Expert Excited for Next Steps With CAR-T in Non-Hodgkin Lymphoma
Ahmed Galal, MD, sheds light on the current use of CAR T-cell therapy in relapsed/refractory lymphomas and a handful of strategies to expand the reach of this therapy.
Targeting Mesothelin May Yield Results in Hard-to-Treat Solid Tumors
Mesothelin, a protein found on cell surfaces and in serum, has emerged as a promising target for immunotherapy-based treatment approaches for several malignancies with poor prognoses and limited treatment options. Investigating novel approaches to optimize delivery and identifying combinations of agents to synergistically improve therapeutic response will be the next steps in bringing mesothelin-targeted therapies into the clinical setting.
The FDA has granted an orphan drug designation to the autologous CAR T-cell therapy P-BCMA-101 for the treatment of patients with relapsed/refractory multiple myeloma.
Early Trials Suggest New Path for CAR T-Cell Therapy in Solid Tumors
Two novel CAR T-cell therapies designed to attack solid tumors are showing signs of antitumor activity and tolerability in early clinical trial findings, fueling optimism about expanding this emerging form of immunotherapy beyond hematologic malignancies.
Nirav N. Shah, MD, discusses the promise of CAR T-cell therapy in hematologic malignancies and highlights recent research exploring sequential CAR-T therapies, armored CAR T cells, as well as other novel approaches.
Research Propels Forward With CAR T-Cell Therapy in Pediatric ALL
Christine N. Duncan, MD, discusses the current components of CAR T-cell therapy in pediatric acute lymphoblastic leukemia.
Publication Bottom Border
Border Publication